Combining the emerging miRNA biomarkers with traditional biomarkers like PSA has been suggested by Gaglani et al. to further enhance the diagnostic accuracy and staging of prostate cancer by integrating multiple biomarkers into tests [190]. The gene discussed is KLK3; the disease is prostate cancer.